Tag - ACOR

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...